Oncolytic adenovirus targeting LASP-1 inhibited renal cell cancer progression
- FANGHAO SUN1, WENCHAO ZHAO1, LIANSHENG ZHANG2, HONGGUI MA1, JIAN ZHOU1, YOUGAN CHEN1, JIANQUAN HOU1,*
1 Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China
2 Department of Urology, Soochow University Affiliated Wuxi Ninth Hospital, Wuxi, 214000, China
* Address correspondence to: Jianquan Hou,
2 Department of Urology, Soochow University Affiliated Wuxi Ninth Hospital, Wuxi, 214000, China
* Address correspondence to: Jianquan Hou,
Received 23 July 2020; Accepted 24 August 2020; Issue published 24 December 2020
Abstract
Recent studies suggested that LIM and SH3 protein 1 (LASP-1) is a promising therapeutic target for renal cell
cancer (RCC). This study aimed to explore the role of LASP-1 in RCC. For this purpose, LASP-1 expression in RCC
tissues was analyzed by immunohistochemistry and Western blot analysis. Cell proliferation, migration, invasion, and
gene expression were detected by CCK-8 assay, Transwell assay, and Western blot analysis. The results showed that
LASP-1 was highly expressed in RCC, and its expression level,t was positively correlated with lymph node metastasis
and tumor, nodes, and metastases (TNM) stage. The knockdown of LASP-1 expression significantly inhibited the
proliferation of RCC cells, increased the apoptosis rate, and inhibited RCC cell invasion and migration by inhibiting
epithelial–mesenchymal transition. We conclude that LASP-1 promotes RCC progression and metastasis and is a
promising therapeutic target for RCC.
Keywords
LASP-1, Oncolytic adenovirus, Renal cell cancer
Cite This Article
SUN, F., ZHAO, W., ZHANG, L., MA, H., ZHOU, J. et al. (2020). Oncolytic adenovirus targeting LASP-1 inhibited renal cell cancer progression. BIOCELL, 44(4), 639–647.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.